173 related articles for article (PubMed ID: 12837149)
1. Factors predicting the response to rituximab in indolent lymphoma.
Lee D
Clin Lymphoma; 2003 Jun; 4(1):19-21. PubMed ID: 12837149
[No Abstract] [Full Text] [Related]
2. First-line and maintenance treatment with rituximab for patients with indolent non-Hodgkin's lymphoma.
Hainsworth JD
Semin Oncol; 2003 Feb; 30(1 Suppl 2):9-15. PubMed ID: 12652459
[TBL] [Abstract][Full Text] [Related]
3. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Cvetković RS; Perry CM
Drugs; 2006; 66(6):791-820. PubMed ID: 16706552
[TBL] [Abstract][Full Text] [Related]
4. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma: interim follow-up of a multicenter phase II trial.
Hainsworth JD
Semin Oncol; 2002 Feb; 29(1 Suppl 2):25-9. PubMed ID: 11842385
[TBL] [Abstract][Full Text] [Related]
5. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma.
Dennie TW; Kolesar JM
Clin Ther; 2009; 31 Pt 2():2290-311. PubMed ID: 20110042
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal antibody therapy for lymphoma.
Campbell P; Marcus R
Blood Rev; 2003 Sep; 17(3):143-52. PubMed ID: 12818224
[TBL] [Abstract][Full Text] [Related]
7. Rituximab in the treatment of non-Hodgkin's lymphoma--a critical evaluation of randomized controlled trials.
Griffin MM; Morley N
Expert Opin Biol Ther; 2013 May; 13(5):803-11. PubMed ID: 23560506
[TBL] [Abstract][Full Text] [Related]
8. Rituximab Improves Rate and Duration of Chemotherapy-Induced Remissions in Indolent and Aggressive Non-Hodgkin's Lymphoma.
Gibson AD
Clin Lymphoma; 2004 Sep; 5(2):81-3. PubMed ID: 15453921
[No Abstract] [Full Text] [Related]
9. Current and ongoing clinical development of immunotherapy in B-cell malignancies. Proceedings of a conference. January 2001, Kailua-Kona, Hawaii, USA.
Semin Oncol; 2002 Feb; 29(1 Suppl 2):1-112; quiz 113-21. PubMed ID: 11876162
[No Abstract] [Full Text] [Related]
10. [Clinical use of monoclonal antibodies in malignant lymphomas].
Schnell R; Hiddemann W; Diehl V; Engert A
Internist (Berl); 2001 Jun; 42(6):815-6, 819-26. PubMed ID: 11449628
[No Abstract] [Full Text] [Related]
11. Spotlight on rituximab in non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Cvetković RS; Perry CM
BioDrugs; 2006; 20(4):253-7. PubMed ID: 16831024
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibodies for the treatment of hematologic malignancies: clinical trials in Japan.
Tobinai K
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S90-6. PubMed ID: 12819934
[TBL] [Abstract][Full Text] [Related]
13. Beyond rituximab: The future of monoclonal antibodies in B-cell non-Hodgkin lymphoma.
Sikder MA; Friedberg JW
Curr Hematol Malig Rep; 2008 Oct; 3(4):187-93. PubMed ID: 20425465
[TBL] [Abstract][Full Text] [Related]
14. [Generalized lymphadenopathy and B symptoms].
Nägelein R
Internist (Berl); 2006 Sep; 47(9):974; author reply 974. PubMed ID: 17245841
[No Abstract] [Full Text] [Related]
15. Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab.
Sacchi S; Federico M; Dastoli G; Fiorani C; Vinci G; Clò V; Casolari B
Crit Rev Oncol Hematol; 2001 Jan; 37(1):13-25. PubMed ID: 11164715
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of bendamustine in rituximab-refractory indolent B-cell non-Hodgkin lymphoma: review of a pivotal trial.
Ujjani C; Cheson B
Future Oncol; 2011 Jan; 7(1):9-14. PubMed ID: 21174533
[TBL] [Abstract][Full Text] [Related]
17. Rituximab therapy of B-cell neoplasms.
Petryk M; Grossbard ML
Clin Lymphoma; 2000 Dec; 1(3):186-94; discussion 195-6. PubMed ID: 11707828
[TBL] [Abstract][Full Text] [Related]
18. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.
Pfreundschuh M; Trümper L; Osterborg A; Pettengell R; Trneny M; Imrie K; Ma D; Gill D; Walewski J; Zinzani PL; Stahel R; Kvaloy S; Shpilberg O; Jaeger U; Hansen M; Lehtinen T; López-Guillermo A; Corrado C; Scheliga A; Milpied N; Mendila M; Rashford M; Kuhnt E; Loeffler M;
Lancet Oncol; 2006 May; 7(5):379-91. PubMed ID: 16648042
[TBL] [Abstract][Full Text] [Related]
19. Rituximab: ongoing and future clinical development.
Grillo-López AJ; Hedrick E; Rashford M; Benyunes M
Semin Oncol; 2002 Feb; 29(1 Suppl 2):105-12. PubMed ID: 11842397
[TBL] [Abstract][Full Text] [Related]
20. Innovative strategies in lymphoma therapy.
Jäger U
Wien Klin Wochenschr; 2003 Aug; 115(13-14):462-70. PubMed ID: 13677264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]